Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,942.00
(
0.87%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.80
(
0.00%
)
Bitcoin
78,252.09
(
-0.54%
)
News Focus
News Focus
Post# of 257484
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122926
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 217396

Tuesday, 07/24/2018 11:21:30 AM

Tuesday, July 24, 2018 11:21:30 AM

Post# of 257484
ABBV/NBIX—FDA approves Orilissa (elagolix) for endometriosis pain:

https://finance.yahoo.com/news/abbvie-receives-u-fda-approval-123000190.html

The US list price is ~$10K/yr. (The recommended course of treatment is two years.)

Orlissa also works for management of uterine fibroids, having hit all endpoints in two phase-3 trials (#msg-138708805), but it is not yet approved in that indication.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today